Medical catheter for drug sustained release

Abstract

The invention relates to the field of medical instruments, in particular to a medical catheter for drug sustained release, which comprises a catheter body and a joint assembly, a main cavity is formed in an inner cavity of the tube body, the front end of the tube body is closed, a through hole communicated with the main cavity is formed in the front section of the tube body, a micropore is formed in the middle section of the tube body, a medicine injection hole is formed in the rear section of the tube body, and an auxiliary cavity communicated between the micropore and the medicine injection hole is formed in the inner cavity of the tube body; the connector assembly comprises a main connector and an auxiliary connector, the rear section of the tube body is sleeved with the connector assembly, the tube body in front of and behind the medicine injection hole is sealed with the connector assembly, the main cavity is communicated with the main connector, and the medicine injection hole is communicated with the auxiliary connector. When the catheter section is indwelling in the body, lidocaine gel can be infused at any time for pain or discomfort of a patient caused by catheter placement, the slow-release anesthesia effect can be achieved, liquid medicine is infused through the auxiliary connector, the good medicine release effect can be achieved through the auxiliary cavity and the micropores formed in the catheter body, operation is easy, and convenience and practicability are achieved.

Description

Technical Field

[0001] This invention relates to the field of medical devices, and more specifically, to a medical catheter for sustained drug release. Background Technology

[0002] Urinary catheters are important invasive medical materials widely used in clinical practice. They are mainly used to address urethral deformities caused by benign prostatic hyperplasia, urethral trauma, sexually transmitted diseases, etc., which prevent normal urination. They are also used for preparation before general anesthesia and spinal anesthesia, and for the resuscitation of critically ill patients. Because urethral size varies among patients, and the urethra is rich in nerve fibers, patients are very sensitive to pain inside the urethra. Patients often experience significant pain during catheter insertion, which can lead to difficulty or failure due to strong contractions of the urethral sphincter and even urethral spasm.

[0003] During the period of indwelling urinary catheterization, the damage caused during insertion and the abrasion from movement can lead to friction damage to the urethral surface, and may even form adhesions later, increasing the patient's pain and causing great inconvenience to the patient's later recovery and daily life. Furthermore, during the period of indwelling urinary catheterization, the patient's discomfort and pain are particularly obvious, and are often accompanied by symptoms of urinary frequency and urgency; moreover, the movement of the indwelling urinary catheter is also very painful due to the pulling of the catheter.

[0004] In addition, the friction between the catheter and the patient's urethral wall during catheter removal can cause intense pain. Furthermore, modern anesthetic catheters typically do not provide a fixed, repeated dose of anesthetic, and the catheter can still cause pain after the anesthesia wears off.

[0005] Enteral nutrition support refers to the artificial feeding of patients through a nasogastric tube inserted into the gastrointestinal tract via one nostril, oral cavity, or gastrointestinal stoma, ensuring that patients can ingest sufficient protein, calories, and other nutrients. However, patients who use nasogastric tubes for a long time often experience varying degrees of skin or mucous membrane damage in the nasal cavity. Moreover, during the period of nasogastric tube placement, the cavity from the nasal cavity to the pharynx follows a curved path from upward to downward. Due to the inherent bending and rebound characteristics of the nasogastric tube, it can compress the inner wall of this cavity, and in severe cases, even cause ulceration, resulting in significant loss and suffering for the patient.

[0006] In summary, whether it is a urinary catheter or a nasogastric tube, patients suffer a great deal of pain during the period of catheter placement. Summary of the Invention

[0007] To address the aforementioned problems, the present invention aims to provide a medical catheter for sustained drug release that alleviates patient suffering.

[0008] The objective of this invention is achieved through the following technical solution: The present invention provides a medical catheter for sustained drug release, comprising: a tube body and a connector assembly; the inner cavity of the tube body has a main lumen, the front end of the tube body is closed, a through hole communicating with the main lumen is opened on the front section of the tube body, a micropore is opened on the middle section of the tube body, a drug injection hole is opened on the rear section of the tube body, and a secondary lumen communicating between the micropore and the drug injection hole is opened in the inner cavity of the tube body. The connector assembly includes a main connector and a secondary connector. The rear section of the tube is fitted inside the connector assembly. The tubes before and after the injection port are sealed with the connector assembly. The main cavity is connected to the main connector, and the injection port is connected to the secondary connector.

[0009] Furthermore, the medical catheter also includes a first sealing sleeve and a second sealing sleeve, which are respectively fitted onto the tube body before and after the injection port and seal with the connector assembly.

[0010] Furthermore, there is an annular cavity between the conduit and the connector assembly between the first and second sealing sleeves, and the annular cavity connects the injection port and the auxiliary connector.

[0011] Furthermore, the tube body is a flexible tube body.

[0012] Furthermore, there is one or more secondary cavities, which are evenly distributed at the edge of the main cavity.

[0013] Furthermore, the through hole is a feeding hole.

[0014] Furthermore, the micropores are arranged in multiple rows along the axial direction of the tube, with each row of micropores corresponding to a secondary cavity.

[0015] Furthermore, the through hole is a drainage hole.

[0016] Furthermore, the medical catheter also includes a balloon, which is placed on the tube body between the drainage hole and the micropore. An additional lumen is provided inside the tube body, and an additional connector is provided in the connector assembly. The balloon, the additional lumen inside the tube body, and the additional connector in the connector assembly are connected in sequence.

[0017] Furthermore, the auxiliary connector is a medical check valve connector.

[0018] The medical catheter for sustained drug release of the present invention can provide sustained-release anesthesia by infusing lidocaine gel at any time during the period when the catheter segment is in the body, in response to the pain or discomfort caused by the catheter insertion. The drug is infused through a secondary connector, and the micropores arranged in the secondary lumen of the catheter body can achieve a good drug release effect. It is simple to operate and convenient to use. Attached Figure Description

[0019] The accompanying drawings, which are included to provide a further understanding of the invention and form part of this application, illustrate exemplary embodiments of the invention and, together with their description, serve to explain the invention and do not constitute an undue limitation thereof. In the drawings: Figure 1 This is an overall structural diagram of the nasogastric tube type for drug sustained release according to the present invention; Figure 2 This is a cross-sectional view of the middle and rear section structure of the nasogastric tube type for drug sustained release of the present invention; Figure 3 This is a structural diagram of the posterior segment of the nasogastric tube type of the medical catheter used for drug sustained release according to the present invention; Figure 4 This is a cross-sectional view of the number of multiple lumens in the nasogastric tube of the medical catheter used for drug sustained release according to the present invention; Figure 5 This is a cross-sectional view of the number of multiple lumens in the medical catheter for sustained drug release according to the present invention; Figure 6 These are different structural diagrams of the connector assembly for a medical catheter-type urinary catheter used for drug sustained release according to the present invention; The attached figures are labeled as follows: 1. Tube body; 2. Connector assembly; 3. Main cavity; 4. Micropore; 5. Injection port; 6. Secondary cavity; 7. First sealing sleeve; 8. Second sealing sleeve; 9. Annular cavity; 10. Feeding port; 11. Drainage port; 12. Balloon; 13. Main connector; 14. Secondary connector. Detailed Implementation

[0020] To enable those skilled in the art to better understand the present invention, the technical solutions of the present invention will be clearly and completely described below with reference to the accompanying drawings of the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort should fall within the scope of protection of the present invention.

[0021] like Figures 1 to 6 As shown in the figure, a medical catheter for sustained drug release according to an embodiment of the present invention mainly has two structures: a urinary catheter type and a nasogastric tube type. The main structures of these two types are identical, and they differ only in the functional structures corresponding to the treatment sites they target.

[0022] Nasogastric tube type: The main structure of the nasogastric tube type consists of a tube body 1, a connector assembly 2, etc. The tube body 1 is a flexible tube with a certain length and a circular outer cross-section. The material can be flexible materials such as silicone, TPU, PVC or latex. The inner cavity of the tube body 1 has a main cavity 3 and a secondary cavity 6. It can be divided into several structural models: tube body 1 with two secondary cavities, tube body 1 with three secondary cavities, tube body 1 with four secondary cavities, and tube body 1 with more secondary cavities.

[0023] The main cavity 3 is located in the center, while the secondary cavities 6 are distributed at the edges of the main cavity 3. The main cavity 3 has a large inner diameter, while the secondary cavity 6 has a small inner diameter. The secondary cavity tube 1 contains two secondary cavities 6, which are symmetrically and evenly distributed at 180 degrees. The secondary cavity tube 1 contains three secondary cavities 6, and the secondary cavity tube 1 contains four secondary cavities 6, all of which are evenly distributed in a circle around the main cavity 3.

[0024] Nasogastric tubes and urinary catheters can also utilize a single injection lumen 6. This injection lumen 6 can have a circular or elliptical cross-section (rectangular cross-sections are also acceptable). When the injection lumen 6 has an elliptical cross-section, the main lumen 3 of the tube body 1 has a semi-circular cross-section. By drilling transversely through the elliptical injection lumen 6 on both sides, a transverse injection hole 5 can be formed on each side of the tube body 1 wall, allowing medication to be evenly infused into both sides of the tube. When the transverse injection holes 5 are evenly spaced along the axial direction of the tube body 1, two sets of evenly spaced transverse injection holes 5 can be formed. This structure can include both transverse and longitudinal injection holes 5. The transverse and longitudinal injection holes 5 can be staggered (or distributed along the same cross-section) along the axial direction of the tube body 1. The tube body 1 can infuse medication at three angles from three different circumferential directions. The urinary catheter, in addition to the nasogastric tube, has a balloon cavity in the tube body 1. At this point, the secondary connector 14 at the rear end of the nasogastric tube and the urinary catheter can directly correspond one-to-one with the drug injection secondary cavity 6 or the balloon cavity, without the need for the annular cavity 9.

[0025] Other structural options: When the nasogastric tube and urinary catheter have two injection lumens 6, two elliptical injection lumens 6 (or rectangular injection lumens 6) can also be used. Similarly, transverse injection holes 5 penetrating both sides of the tube wall can be provided, or longitudinal injection holes 5 penetrating only one side can be provided. In this case, the tube wall can form up to six sets of injection holes 5, which can achieve uniform coverage of drug diffusion across all areas of the circumference of the tube body 1, forming a drug coverage without dead angles.

[0026] Other structural options: Based on the main options of nasogastric tube and urinary catheter, the second sealing sleeve 8 can be designed as an integral part of the connector assembly 2, with the aim of forming an annular cavity 9 to achieve the purpose of this structure.

[0027] Other structural options: Based on the main options of nasogastric tube and urinary catheter, the injection port 5 of the tube body 1 with 9 segments of annular cavity can also be replaced from a structure of several micro-holes 4 in each group to a larger elongated hole in each group. The purpose is to improve the permeability of the drug when it is infused into the injection port 6.

[0028] The feeding port 10 is located at the front of the nasogastric tube. This feeding port 10 is a side hole on the tube wall, and is circular or elliptical in shape. The feeding port 10 connects to the main lumen 3 and is used to deliver the nutrient solution to the patient's stomach or intestines. A certain distance behind the feeding port 1, on the tube body 1, micropores 4 are evenly spaced on the tube wall. The micropores 4 can be arranged coaxially or staggered. The secondary lumens 6 on the inner wall of the tube body 1 extend to the section containing the micropores 4. Each micropore 4 connects to its corresponding secondary lumen 6. The number of rows of micropores 4 corresponds to the number of secondary lumens 6, and the corresponding micropores 4 are evenly spaced in the axial direction.

[0029] A first sealing sleeve 7 and a second sealing sleeve 8 are fitted on the wall of the nasogastric tube 1 at the rear end. The first sealing sleeve 7 and the second sealing sleeve 8 are cylindrical and have a certain wall thickness. The two sealing sleeves are made of silicone or other flexible sealing materials. There is a certain distance between the first sealing sleeve 7 and the second sealing sleeve 8. On the tube 1 between the two sealing sleeves, on the tube wall corresponding to the secondary cavity 6, there are also a number of drug injection holes 5 that are evenly arranged circumferentially and axially.

[0030] The rear end of the tube body 1 is integrally connected to the connector assembly 2. The connector assembly 2 includes a main connector 13 and a secondary connector 14. The tube body 1 is fixedly sleeved onto the sleeve section in front of the connector assembly 2. The first sealing sleeve 7 and the second sealing sleeve 8 on the outside of the tube body 1 are tightly fixed to the sleeve section. The first sealing sleeve 7 and the second sealing sleeve 8 ensure a seal with the inner wall of the sleeve section. The outside of the tube body 1 between the two sealing sleeves and the inner wall of the sleeve section of the connector assembly 2 form an annular cavity 9, which allows the annular cavity 9 to connect to the injection holes 5 of all the secondary cavities 6. The internal through-channel of the secondary connector 14 of the connector assembly 2 directly connects to the annular cavity 9, thereby enabling one secondary connector 14 to deliver drugs to all the secondary cavities 6 through the injection holes 5 and for the drugs to overflow through the micropores 4.

[0031] When the nasogastric tube 1 is inserted through the patient's nasal cavity, down the esophagus, and extends to the stomach or intestines, the micro-hole 4 is positioned precisely in the area from the nasal cavity to the pharynx. If the patient experiences pain or discomfort in this area, lidocaine gel can be injected using a positive pressure infusion device such as a syringe through the posterior connector 14. If the inner wall of the nasal cavity to pharynx becomes ulcerated or infected due to catheter movement or pressure, anti-inflammatory medication can be injected for treatment.

[0032] The main structure of the urinary catheter type is basically the same as that of the nasogastric tube type. The front end of the catheter body 1 has a circular or elliptical drainage hole 11, which communicates with the main lumen 3. The balloon 12 is located behind the drainage hole 11. Micropores 4 are evenly distributed on the catheter body 1 behind the balloon 12. The length of the micropores 4 in the urinary catheter type basically covers the entire length of the human urinary tract, enabling sustained-release anesthesia or anti-inflammatory treatment of the entire urethra. The catheter body 1 of the urinary catheter type has an additional secondary lumen 6 compared to the nasogastric tube type, used to connect to the balloon 12. Similarly, an additional secondary connector 14 is added to the connector assembly 2, used to connect to the secondary lumen 6 corresponding to the balloon 12, for inflating and deflating the balloon 12.

[0033] The auxiliary connector 14 can be fitted with a sealing cap to provide a seal when not in use. Alternatively, the auxiliary connector 14 can also be a medical check valve connector of known technology.

[0034] The innovative technical points and beneficial effects of this invention are as follows: 1. Compared to traditional nasogastric tubes and urinary catheters, this application's technology adds evenly distributed circumferential and axially spaced micropores 4 to one segment of the catheter body. These micropores allow for sustained-release anesthesia via lidocaine gel infusion to address pain or discomfort caused by catheter insertion during the catheter's indwelling position. Furthermore, it allows for anti-inflammatory treatment of infections caused by catheter compression or abrasion of the urethral or nasal cavity walls leading to the pharynx, eliminating the need for catheter removal due to patient intolerance.

[0035] 2. The technology of this application enables drug infusion through a single auxiliary connector 14, simultaneously releasing medication into multiple auxiliary cavities 6 and all micropores 4 arranged circumferentially on the catheter body 1. The first sealing sleeve 7 and the second sealing sleeve 8, in conjunction with the connector assembly 2, form an annular cavity 9 between the inner wall of the connector assembly 2 channel and the outer wall of the catheter body 1. This allows for simultaneous infusion through the uniformly arranged injection holes 5 corresponding to the multiple auxiliary cavities 6, achieving the goal of simultaneous infusion into all micropores 4. This ensures uniform drug release around the catheter circumference, avoiding uneven drug absorption in the nasal or urethral segments, which could affect the effectiveness of anesthesia or anti-inflammatory treatment.

[0036] 3. The first sealing sleeve 7 and the second sealing sleeve 8 are made of silicone or other flexible sealing materials. Together with the injection hole 5 between the two sealing sleeves, the two sealing sleeves are close to the inner channel of the connector assembly 2, serving both to fix the connection to the connector assembly 2 and to seal both ends of the annular cavity 9. Furthermore, in terms of mold design and manufacturing process, this avoids the problem of negative angle annular grooves in the internal structure of the connector assembly 2, which would otherwise lead to a sharp increase in cost and manufacturing difficulty. This structural design ensures stable performance, simplifies the manufacturing process, and significantly reduces costs.

[0037] 4. The micropore 4 can be equipped with two, three, four or more secondary cavities 6, or evenly distributed. The technical structure of this application can realize the infusion of any number of secondary cavities 6 into the unified secondary connector 14, and the simultaneous release of the drug from all the circumferentially distributed micropores 4.

[0038] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A medical catheter for sustained drug release, characterized in that, include: Tube body and connector assembly; the inner cavity of the tube body has a main cavity, the front end of the tube body is closed, the front section of the tube body has a through hole communicating with the main cavity, the middle section of the tube body has a micro hole, the rear section of the tube body has an injection hole, and the inner cavity of the tube body has a secondary cavity communicating between the micro hole and the injection hole; The connector assembly includes a main connector and a secondary connector. The rear section of the tube is sleeved inside the connector assembly. The tube before and after the injection port is sealed to the connector assembly. The main cavity is connected to the main connector, and the injection port is connected to the secondary connector.

2. The medical catheter for sustained drug release according to claim 1, characterized in that, The medical catheter also includes a first sealing sleeve and a second sealing sleeve, which are respectively fitted onto the tube body before and after the injection port to seal with the connector assembly.

3. The medical catheter for sustained drug release according to claim 2, characterized in that, An annular cavity exists between the conduit and the connector assembly between the first and second sealing sleeves, the annular cavity connecting the injection port and the auxiliary connector.

4. The medical catheter for sustained drug release according to claim 1, characterized in that, The tube is a flexible tube.

5. The medical catheter for sustained drug release according to claim 1, characterized in that, The number of secondary cavities is one or more, and they are evenly distributed at the edge of the main cavity.

6. The medical catheter for sustained drug release according to claim 1, characterized in that, The through hole is a feeding hole.

7. The medical catheter for sustained drug release according to claim 1, characterized in that, The micropores are arranged in multiple rows along the axial direction of the tube, with each row of micropores corresponding to one of the secondary cavities.

8. The medical catheter for sustained drug release according to claim 1, characterized in that, The through hole is a drainage hole.

9. The medical catheter for sustained drug release according to claim 8, characterized in that, The medical catheter also includes a balloon, which is disposed on the tube body between the drainage hole and the micropore. An additional lumen is provided inside the tube body, and an additional connector is provided in the connector assembly. The balloon, the additional lumen inside the tube body, and the additional connector in the connector assembly are connected in sequence.

10. The medical catheter for sustained drug release according to claim 1, characterized in that, The auxiliary connector is a medical one-way valve connector.

Images